AAAAAA
Results:
1-17
|
Results: 17
Authors:
Weigmann, H
Hartter, S
Maehrlein, S
Kiefer, W
Kramer, G
Dannhardt, G
Hiemke, C
Citation: H. Weigmann et al., Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography, J CHROMAT B, 759(1), 2001, pp. 63-71
Authors:
Hartter, S
Wang, XM
Weigmann, H
Friedberg, T
Arand, M
Oesch, F
Hiemke, C
Citation: S. Hartter et al., Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin, J CL PSYCH, 21(2), 2001, pp. 167-174
Authors:
Muller, MJ
Hartter, S
Kohler, D
Hiemke, C
Citation: Mj. Muller et al., Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: A pilot study, PHARMACOPS, 34(1), 2001, pp. 27-32
Authors:
Weigmann, H
Gerek, S
Zeisig, A
Muller, M
Hartter, S
Hiemke, C
Citation: H. Weigmann et al., Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: Evidence from a therapeutic drug monitoring service, THER DRUG M, 23(4), 2001, pp. 410-413
Authors:
Hartter, S
Morita, S
Bodin, K
Ursing, C
Tybring, G
Bertilsson, L
Citation: S. Hartter et al., Determination of exogenous melatonin and its 6-hydroxy metabolite in humanplasma by liquid chromatography-mass spectrometry, THER DRUG M, 23(3), 2001, pp. 282-286
Authors:
Laine, K
Tybring, G
Hartter, S
Andersson, K
Svensson, JO
Widen, J
Bertilsson, L
Citation: K. Laine et al., Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test, CLIN PHARM, 70(4), 2001, pp. 327-335
Authors:
Hartter, S
Ursing, C
Morita, S
Tybring, G
von Bahr, C
Christensen, M
Rojdmark, S
Bertilsson, L
Citation: S. Hartter et al., Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: A pilot study, CLIN PHARM, 70(1), 2001, pp. 10-16
Authors:
Hartter, S
Weigmann, H
Hiemke, C
Citation: S. Hartter et al., Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection, J CHROMAT B, 740(1), 2000, pp. 135-140
Authors:
Weigmann, H
Hartter, S
Bagli, M
Hiemke, C
Citation: H. Weigmann et al., Steady state concentrations of clomipramine and its major metabolite desmethylclomipramine in rat brain and serum after oral administration of clomipramine, EUR NEUROPS, 10(5), 2000, pp. 401-405
Authors:
Hiemke, C
Hartter, S
Citation: C. Hiemke et S. Hartter, Pharmacokinetics of selective serotonin reuptake inhibitors, PHARM THERA, 85(1), 2000, pp. 11-28
Authors:
Hartter, S
Grozinger, M
Weigmann, H
Roschke, J
Hiemke, C
Citation: S. Hartter et al., Increased bioavailability of oral melatonin after fluvoxamine coadministration, CLIN PHARM, 67(1), 2000, pp. 1-6
Fluvoxamine strongly inhibits melatonin metabolism in a patient with low-amplitude melatonin profile
Authors:
Grozinger, M
Hartter, S
Wang, XM
Roschke, J
Hiemke, C
Citation: M. Grozinger et al., Fluvoxamine strongly inhibits melatonin metabolism in a patient with low-amplitude melatonin profile, ARCH G PSYC, 57(8), 2000, pp. 812-813
Authors:
Weigmann, H
Hartter, S
Fischer, V
Dahmen, N
Hiemke, C
Citation: H. Weigmann et al., Distribution of clozapine and desmethylclozapine between blood and brain in rats, EUR NEUROPS, 9(3), 1999, pp. 253-256
Authors:
Grozinger, M
Hartter, S
Hiemke, C
Roschke, J
Citation: M. Grozinger et al., Oxybutynin enhances the metabolism of clomipramine and dextrorphan possibly by induction of a cytochrome P450 isoenzyme, J CL PSYCH, 19(3), 1999, pp. 287-289
Authors:
Szegedi, A
Anghelescu, I
Wiesner, J
Schlegel, S
Weigmann, H
Hartter, S
Hiemke, C
Wetzel, H
Citation: A. Szegedi et al., Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: Drug monitoring and tolerability data from a prospective clinical trial, PHARMACOPS, 32(4), 1999, pp. 148-153
Authors:
Lammers, CH
Deuschle, M
Weigmann, H
Hartter, S
Hiemke, C
Heese, C
Heuser, I
Citation: Ch. Lammers et al., Coadministration of clozapine and fluvoxamine in psychotic patients - Clinical experience, PHARMACOPS, 32(2), 1999, pp. 76-77
Authors:
Hartter, S
Dingeldein, E
Bonath, KH
Citation: S. Hartter et al., Replacement parts of bone - therapeutic agents of future in small animal practice, KLEINTIER P, 43(11), 1998, pp. 813
Risultati:
1-17
|